# Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

> **NCT01951885** · PHASE3 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 101 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Acute Biphenotypic Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Non-Hodgkin Lymphoma
- Hodgkins Disease
- Chronic Lymphocytic Leukemia
- Multiple Myeloma

## Interventions

- **DRUG:** tacrolimus
- **DRUG:** methotrexate
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Methotrexate (low dose)

## Key facts

- **NCT ID:** NCT01951885
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-07
- **Primary completion:** 2020-10-09
- **Final completion:** 2021-08-11
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01951885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01951885, "Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01951885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*